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Abstract
Background: While three countries in South Asia decided to eliminate anthroponotic visceral leishmaniasis (VL) by 2015, its
control in other regions seems fraught with difficulties. Is there a scope for more effective VL control in the Americas where
transmission is zoonotic? We reviewed the evidence on VL control strategies in Latin America—diagnosis, treatment,
veterinary interventions, vector control—with respect to entomological and clinical outcomes.
Methodology/Principal Findings: We searched the electronic databases of MEDLINE, LILACS, and the Cochrane Central
Register of Controlled Trials, from 1960 to November 2008 and references of selected articles. Intervention trials as well as
observational studies that evaluated control strategies of VL in the Americas were included. While the use of rapid
diagnostic tests for VL diagnosis seems well established, there is a striking lack of evidence from clinical trials for drug
therapy and few well designed intervention studies for control of vectors or canine reservoirs.
Conclusion: Elimination of zoonotic VL in the Americas does not seem a realistic goal at this point given the lack of political
commitment, gaps in scientific knowledge, and the weakness of case management and surveillance systems. Research
priorities and current strategies should be reviewed with the aim of achieving better VL control.
Citation: Romero GAS, Boelaert M (2010) Control of Visceral Leishmaniasis in Latin America—A Systematic Review. PLoS Negl Trop Dis 4(1): e584. doi:10.1371/
journal.pntd.0000584
Editor: Hechmi Louzir, Institut Pasteur de Tunis, Tunisia
Received July 15, 2009; Accepted December 1, 2009; Published January 19, 2010
Copyright:  2010 Romero, Boelaert. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This review has partial financial support from BIREME/OPAS/OMS. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: Authors declare no competing interest, actual or perceived that could bias the presented work.
* E-mail: gromero@unb.br
Introduction
Visceral leishmaniasis (VL) in Latin America is a severe systemic
disease caused by an intracellular protozoon, Leishmania infantum
(syn. L. chagasi). VL is a zoonosis: the domestic dog is the main
animal reservoir, while foxes and other wild animals play a role in
sylvatic transmission [1–5]. The parasite is transmitted by a night-
biting sandfly, Lutzomyia longipalpis, a 2 to 3 mm-long insect well
adapted to the peri-domestic environment and distributed
throughout Latin America [6–10]. L. infantum is also transmitted
by Lu. cruzi in Brazil [11] and Lu. evansi in Colombia, and
Venezuela [12,13]. Clinically, VL is characterized by prolonged
fever, weight loss, hepatomegaly, splenomegaly, hypergamma-
globulinemia and pancytopenia and it is usually fatal if not
adequately treated [14]. Not all L. infantum infections lead to overt
clinical disease: in Brazil ratios of 8–18 incident asymptomatic
infections to 1 incident clinical case were described [15–17]. Risk
factors for the development of clinical disease are only partially
understood. Some studies suggest that the susceptibility to VL
could be genetically determined [18–22]. Malnutrition places
children at higher risk [23,24]. Other studies identified being a
young male and the presence of animals in the neighborhood [25],
living in houses with a inadequate sewage system and waste
collection [26], and residence in an urban slum or in areas with
green vegetation [27] as risk factors.
T h eV Ld i s e a s eb u r d e ni nL a t i nA m e r i c ai sn o te x a c t l yk n o w n
because most countries lack effective surveillance systems [28–
30]. Brazil declared a total of 50,060 clinical VL cases between
1990 and 2006 and this number accounts for 90% of all reported
VL cases in the Americas, but is subject to substantial
underreporting [29,31]. The country reported so far 176 HIV-
coinfected VL cases [32] but has a significant number of
asymptomatic co-infected individuals [33,34]. Whereas VL was
initially concentrated in the poor rural areas in the northeast of
the country, since the 1980s epidemics have occurred in major
cities such as Belo Horizonte, Campo Grande, Natal, and others
[35–37]. Some of these urban VL outbreaks were attributed to the
migration of families from the rural areas to the peri-urban slums
after periods of prolonged drought. Whereas the reported VL
incidence in the 1980s averaged at 1,500 cases per year, this figure
increased to an average 3,362 per year between 2000 and 2006
[31]. The disease has gradually spread south and eastward and is
reported since 1999 from the states of Sa ˜oPauloandMatoGrosso
do Sul [38]. Human VL cases have also been reported from
Honduras [39], Venezuela [40], Paraguay [41] and Argentina
[42]. Sporadic and/or import human or canine cases were
described in Chile [43], Ecuador [44], Bolivia [45], Mexico [46],
Costa Rica [47], and French Guyana [48]. A geographically
referenced database providing links to published literature about
the spatial distribution of VL can be accessed on http://apps.
www.plosntds.org 1 January 2010 | Volume 4 | Issue 1 | e584who.int/tools/geoserver/www/ecomp/index.html (Accessed on
September 19 2009).
Control of VL in the Americas has proved challenging. Early
diagnosis and treatment is essential for the patient, but has limited
impact on transmission if the main animal reservoir or insect
vectors are not tackled [49]. Some studies showed a decreased
incidence of VL in both dogs and children following serological
screening and culling of seropositive dogs [50,51], but this control
strategy is increasingly debated [52]. Human VL incidence
remained high in Brazil despite intensive application of this
strategy in recent years [31]. Lack of impact has been attributed to
the low sensitivity of the diagnostic tests, the long delay between
diagnosis and culling and the low acceptance of culling by dog
owners. Mathematical modeling suggests that vector control and
vaccination of dogs would be more efficacious than dog culling
[49]. Treatment of infected dogs is not an effective strategy as
relapses are frequent, and dogs quickly become infectious again
[53]. A controlled trial in a different setting of zoonotic VL (Iran)
showed how the use of deltamethrin-treated dog collars reduced
the risk of infection in dogs (by 54%) and in children (by 43%)
[54]. Another controlled trial in Brazil showed only a modest effect
on canine seroconversion rates [55] in spite of the proven effect of
deltamethrin-impregnated dog collars on vector density [56].
In the Mediterranean region, where VL is also zoonotic with
dogs playing a role as main reservoirs, human cases and canine
cases are treated with antiparasitic drugs. In Europe, individual
measures to protect dogs from sand fly bites using insecticides are
common practices, but no public health surveillance and control
interventions such as those applied in Brazil are in place [57].
Recently, the governments of India, Bangladesh and Nepal
launched a VL elimination initiative, aiming to reduce the annual
incidence of VL to less than 1/10,000 population by 2015 [58].
The strategy exploits recent technological developments in
diagnosis, drugs and vector control [59]. Though the transmission
pattern in this region is totally different, with L. donovani being the
causative agent, a different sandfly vector (P. argentipes) and -most
importantly- anthroponotic instead of zoonotic transmission, we
wanted to examine whether there is a scope for VL elimination or
at least improved control in the Americas. Given the heterogeneity
in causative species, vector and transmission pattern, evidence on
VL control tools from one region cannot be readily extrapolated to
another. We report a review of the literature on the effectiveness of
novel VL control tools and strategies in Latin-America structured
around diagnosis of human and canine VL, treatment of human
cases and control of the animal reservatoir and arthropod vectors.
Methods
The review on VL control interventions was structured around
the following topics: (i) Diagnosis of human VL; (ii) Treatment of
human VL; (iii) Diagnosis of canine VL; (iv) Control of the animal
reservoir and vector. Box 1 shows the Medical Subject Heading
(MeSH) terms and keywords used in the search per topic. We
searched for English, Portuguese and Spanish–language articles in
MEDLINE, LILACS, as well as the Cochrane Central Register of
Controlled Trials from 1960 to November 2008. We considered
only original research, mainly but not exclusively intervention
trials, diagnostic accuracy studies and observational studies, with
scope targeted to American VL. Additional articles were obtained
through citation tracking of review and original articles.
Box 1. Keywords and MESH Headings Used for
Literature Searches
Diagnosis of human VL: For the PubMed search:
(visceral leishmaniasis OR kala-azar OR L.infantum
OR L. chagasi OR L.donovani OR Leishmania infantum
OR Leishmania chagasi OR Leishmania donovani) AND
(diagnostic accuracy OR diagnostic performance
OR sensitivity OR specificity OR validation) AND
‘‘Americas’’ [MeSH]. For the LILACS search the key-
words: leishmaniasis AND visceral AND (diagnosis
OR DAT OR dipstick) were used.
Treatment of human VL: For the PubMed search the
following key-words were used: (visceral leishmaniasis
OR kala azar OR L. chagasi OR L donovani) AND
(amphotericin b OR glucantime OR sodium stibo-
gluconate OR miltefosine OR sitamaquine OR
pentavalent antimonials OR paromomycin) AND
‘‘Americas’’ [MeSH]. For the LILACS search the key-
words: leishmaniasis AND visceral AND treatment
were used. For the Cochrane Central Register of Controlled
Trials we used the term visceral leishmaniasis because
the search with the key-words and MeSH terms used for
the PubMed searching failed to retrieve any paper.
Diagnosis of canine VL: For the PubMed search:
(canine visceral leishmaniasis OR L.infantum OR
L.chagasi OR L.donovani OR Leishmania infantum OR
Leishmania chagasi OR Leishmania donovani) AND
(diagnostic accuracy OR diagnostic performance
OR sensitivity OR specificity OR validation) AND
‘‘Americas’’ [MeSH]. For the LILACS search the key-
words: canine AND leishmaniasis AND visceral AND
diagnosis were used.
Control of the animal reservoir and arthropod
vector: for the PubMed search: (visceral leishmaniasis
OR Leishmania chagasi OR L chagasi OR Kala-azar OR
Leishmania infantum) AND ‘‘Americas’’ [MeSH] AND
control. The LILACS search was performed using the term
visceral leishmaniasis OR leishmaniose visceral OR
leishmaniasis visceral because of the failure to retrieve
any paper when using the PubMed approach.
Author Summary
Visceral leishmaniasis is a vector-borne disease character-
ized by fever, spleen and liver enlargement, and low blood
cell counts. In the Americas VL is zoonotic, with domestic
dogs as main animal reservoirs, and is caused by the
intracellular parasite Leishmania infantum (syn. Leishmania
chagasi). Humans acquire the infection through the bite of
an infected sand fly. The disease is potentially lethal if
untreated. VL is reported from Mexico to Argentina, with
recent trends showing a rapid spread in Brazil. Control
measures directed against the canine reservoir and insect
vectors have been unsuccessful, and early detection and
treatment of human cases remains as the most important
strategy to reduce case fatality. Well-designed studies
evaluating diagnosis, treatment, and prevention/control
interventions are scarce. The available scientific evidence
reasonably supports the use of rapid diagnostic tests for
the diagnosis of human disease. Properly designed
randomized controlled trials following good clinical
practices are needed to inform drug policy. Routine
control strategies against the canine reservoirs and insect
vectors are based on weak and conflicting evidence, and
vector control strategies and vaccine development should
constitute research priorities.
Visceral Leishmaniasis in Latin America
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the studies was examined to identify relevant papers for the review.
Data were extracted by one researcher directly from the full length
articles to structured tables containing all the descriptive variables
and relevant outcomes. The inclusion criteria, data extracted for
each item and summary measures are listed below.
Human diagnosis
As we have stated above, we set out to examine whether the
existing control tools allow for elimination of VL in the Americas.
The goal of elimination requires diagnostic and therapeutic tools
that are very easy to use and can be easily decentralized. The World
Health Organization now considers two ‘rapid diagnostic tests’ as
appropriate for the diagnosis of VL in control programs: the Direct
Agglutination Test (DAT) based on whole promastigotes of L.
donovani or L. infantum and the rK39-ICT [60–62]. As it was not our
intention to go into a full review of the available diagnostic tools for
VL, we have excluded PCR and serological tests that require
substantial laboratory equipment, even though there is extensive
experience with the use of IFAT and ELISA tests in the Americas.
Moreover, the clinical benefit of antigen-detection and PCR tests
still needs to be demonstrated [63,64]. We therefore limited our
systematic review to DAT and rK39-ICT.
The eligibility criteria included: original studies evaluating the
DAT or the rK39 immunochromatographic test (ICT); clinical
visceral leishmaniasis diseases in humans as target condition;
adequate reference classification; absolute numbers of true-positive,
true-negative, false-positive and false-negative observations avail-
able or derivable from the data presented. Accuracy measures were
summarized as sensitivity and specificity.
Human treatment
Clinical trials including uncontrolled and retrospective studies
with description of the following characteristics: intervention; case
definition; follow-up schedule; therapeutic endpoints; control
group; and efficacy measure defined through cure and failure
proportions for each treatment.
Canine diagnosis
Original studies evaluating any diagnostic test for canine
leishmaniasis; Leishmania infection and/or VL disease in domestic
dogs as target condition; adequate reference classification; absolute
numbers of true-positive, true-negative, false-positive and false-
negativeobservations available or derivable from the data presented.
Accuracy measures were summarized as sensitivity and specificity.
Vector control and animal reservoir control
Field trials of control measures (canine culling, impregnated dog
collars, canine vaccination, insecticide spraying, insecticide treated
bednets, environmental management) evaluating at least one control
measure; description of the intervention under analysis; target popu-
lation, sampling and randomization process; adequate case definitions
for asymptomatic infection or VL; definition of outcomes related to
humans, dogs or sand flies; at least one effect measure; and at least one
point estimation for the magnitude of the expected effect.
Results
Human diagnosis
A Medline search generated 77 papers, and LILACS 179. After
screening the titles and abstracts of those papers for evaluations of the
DAT or rK39 in human VL, we retrieved eight original papers
(Figure 1 and Table 1). We report only descriptive statistics of
sensitivity and specificity estimates; without drawing conclusions
about differences in these parameters between tests and discuss them
in comparison with results of a meta-analysis by Chappuis et al. [65].
I: Direct agglutination test (DAT) for VL. Andrade et al
(1989) were the first to report a proof-of-principle evaluation of
the DAT in Brazil [66]. A recent meta-analysis of the DAT
performance showed sensitivity and specificity estimates of 94.8%
(95%CI: 92.7–96.4) and 97.1% (95%CI: 93.9–98.7), respectively
[65]. The performance of DAT was neither influenced by the
region nor by the Leishmania species. However, this meta-analysis
included only two studies from Latin –America, both from Brazil,
and both with small sample sizes. Garcez et al (1996) reported
100% sensitivity on 16 parasitologically confirmed VL cases and
98.3% specificity on a mixed group of 65 healthy endemic controls
and patients with other diseases [67]. Schallig et al (2002) reported
100% sensitivity on 21 confirmed VL cases and 100% specificity
on 19 healthy controls and 42 samples of patients with other
diseases [68]. More recently, Teran-Angel et al (2007) reported
100% sensitivity on 30 confirmed VL patients in Venezuela and
100% specificity on 39 controls [69]. Pedras et al (2008) compared
the freeze-dried DAT (FD-DAT) and a locally produced DAT
with 3 other serological tests (rK39 ELISA, ELISA-L. chagasi and
IgG-IFAT) and concluded that the FD-DAT was the most
efficient, with 96.6% sensitivity (n=88) and 98.1% specificity
(n=105) [70]. All reported studies are laboratory-based, no large
prospective clinical studies evaluating the DAT have been
reported from the Americas.
II: rK39-based immunochromatographic test (ICT).
Delgado et al (2001) evaluated the rK39-ICT in Venezuela,
reporting 87.8% sensitivity (36/41 confirmed VL) and a specificity
of 100%. The lower sensitivity was attributed to the fact that the
false negative sera had been kept at 270u for more than 10 years
[71]. A meta-analysis of 13 studies of the rK3 ICT by Chappuis
et al (2006) showed sensitivity and specificity estimates of 93.9%
(95%CI: 87.7–97.1) and 95.3% (95%CI: 88.8–98.1), respectively,
with some regional variation [65]. This meta-analysis included
only two studies from Latin-America [68,72]. De Assis et al (2008)
Figure 1. Flow of inclusion of studies on human VL diagnosis.
doi:10.1371/journal.pntd.0000584.g001
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prospective study in Brazil, with 93% sensitivity on 213 confirmed
VL cases and 97% specificity on 119 controls with clinical sus-
picion of VL but with confirmation of other diseases [73]. On this
basis, it seems that rK39 based diagnosis can be adopted in clinical
practice, though each new brand put on the market should be
evaluated in proper phase-3 designs.
III: Key questions for control.
1. What should be the diagnostic algorithms for VL for use in
primary health care and in active case detection campaigns?
2. How to assure the quality of available VL rapid diagnostic
tests?
3. How to define asymptomatic infected individuals (and how to
manage them?)
4. How to improve clinician’s awareness about the possibility of
Leishmania co-infection in HIV/AIDS cases?
IV: Questions for research.
1. What can be the contribution of novel (molecular) parasite
detection tests to clinical diagnosis?
2. What is the performance of diagnostic assays in HIV-Leishmania
co-infections?
3. What is the performance of antibody-assays in patients from
areas with sympatric circulation of parasites causing cutaneous
leishmaniasis?
Canine diagnosis
Seventy-seven papers were retrieved from Medline/PubMed
search and 11 of them were considered relevant. The LILACS
database search retrieved 26 papers of which 2 were considered
relevant, but 1 was already obtained from the PubMed database
(Figure 2).Finally, 12papers wereincluded inthe review, covering 5
serological tests for canine VL: IFAT, ELISA, dot-ELISA, DAT,
Table 1. Main characteristics of diagnostic accuracy studies reporting on tests for human visceral leishmaniasis in Latin America.
Country
Type of
study
Diagnostic
test
Reference
test
Number of
confirmed VL Sensitivity
Number of
controls Specificity Ref.
Brazil Phase-2 DAT Not described 33 94% 173 OD*** 100% [66]
178 HEC**** 100%
Brazil Phase-2 DAT Parasitology or improving
after antimonial treatment
16 100% 102 OD 100% [67]
105 HEC 100%
Brazil/other Phase-2 FD-DAT* Parasitology 36 100% 42 OD 100% [68]
19 HEC 100%
Venezuela Phase-2 FD-DAT Parasitology 30 100% 20 OD 100% [69]
19 HEC 100%
Brazil Phase-2 FD-DAT Parasitology 88 96.6% 85 OD 97.6% [70]
20 HEC 100%
Venezuela Phase-2 rK39 ICT Composite reference ** 41 87.8% 76 OD 100% [71]
Brazil/other Phase-2 rK39 ICT Parasitology 36 85.7% 42 OD 80.9% [68]
19 HEC 84.2%
Brazil Phase-2 rK39 ICT Parasitology 128 90% 50 OD 100% [72]
10 HEC 100%
Brazil Phase-3 rK39 ICT Parasitology 213 93% 119 OD 97% [73]
*FD-DAT: Freeze-dried DAT.
**Composite reference: at least 2 positive tests out of 4 (bone marrow, IFAT, CIEP, Western blot).
***OD : patients with other, potentially cross-reacting infectious diseases.
****HEC: Healthy Endemic Controls.
Phase 2: Case-Control design, laboratory based study on banked serum samples.
Phase 3: Prospective clinical study, recruiting representative patients, all presenting with febrile splenomegaly.
doi:10.1371/journal.pntd.0000584.t001
Figure 2. Flow of inclusion of studies on canine VL diagnosis.
doi:10.1371/journal.pntd.0000584.g002
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the Brazilian Ministry of Health for its dog screening-and-culling
campaigns. Published estimates for sensitivity range from 72–100%,
for specificity 52–100% (Table 2). The moderate sensitivity and
specificity of this test, the long turn-around time between sample
taking and culling, and the complexity of its execution have been
invoked as one of the reasons for the low effectiveness of the culling
campaign. Several ELISA tests have been evaluated, with assays
based on homologous antigens usually showing higher sensitivity.
Evansetal (1999)showed a highersensitivityofELISAcomparedto
IFAT and pleaded for a revision of the screening policy [84].
Recently more ‘‘user-friendly’’ diagnostics as the DAT and a
canine version of the rK39-ICT were evaluated with good results.
For the freeze-dried DAT sensitivity ranged from 85–100%,
specificity 89–100% [65,76,78] and for the rk39-ICT sensitivity
ranged from 72–96%, specificity 62–100% [81,82]. The main
advantage of these rapid tests would be to shorten the delay
between diagnosis and culling/treatment. However, the reported
estimates of sensitivity in the above studies depend on the type of
dogs included in the ‘‘true cases’’ group with higher sensitivity
observed in symptomatic than in asymptomatically dogs, and
unfortunately, several evaluations failed to include an adequate
Table 2. Main characteristics of diagnostic tests for canine visceral leishmaniasis in Latin America.
Country
Diagnostic
test
Reference
test
Number of
confirmed VL Sensitivity
Number and type
of controls Specificity Ref.
Brazil IFAT Parasitology 46 78% 102 NEC 100% [74]
Brazil IFAT Parasitology 21 100% 14 NEC 100% [66]
Brazil IFAT Parasitology 112 72% 20 NEC 100% [75]
20 OD 52%
Brazil IFAT CRS 36 100% 67 EC 66% [76]
Brazil cELISA Parasitology 46 98% 102 NEC 99% [74]
Brazil cELISA Parasitology 21 71% 14 NEC 86% [66]
Brazil cELISA Parasitology 106 98–100 25 HEC 100% [77]
Brazil cELISA Parasitology 112 95% 20 NEC 100% [75]
20 OD 64%
Brazil cELISA Parasitology 76 95% 33 NEC 100% [78]
Brazil cELISA Parasitology 50 symptomatics 88% 25 NEC 100% [79]
50 asymptomatics 30% 14 OD 64%
Brazil rK39 ELISA Parasitology 106 98.1% 25 HEC 100% [77]
Brazil rK39ELISA Parasitology 50 symptomatics 100% 25 NEC 100% [79]
50 asymptomatics 66% 14 OD 71%
Brazil rK26 ELISA Parasitology 106 99.1% 25 HEC 100% [77]
Brazil rK26ELISA Parasitology 50 symptomatics 94% 25 NEC 100% [79]
50 asymptomatics 66% 14 OD 57%
Brazil rA2ELISA Parasitology 50 symptomatics 70% 25 NEC 100% [79]
50 asymptomatics 88% 14 OD 93%
Brazil Dot-ELISA Parasitology 37 97% 63 HEC 100% [80]
30 NEC 100%
Brazil DAT Parasitology 21 71% 14 NEC 71% [66]
Brazil DAT Parasitology 112 93% 20 NEC 100% [75]
20 OD 95%
Brazil FD-DAT CRS* 36 100% 67 EC 89.5% [76]
Venezuela FD-DAT Parasitology 26 85% 16 HEC 100% [69]
Brazil rK39 ICT CRS** 74 72 101 HEC 61% [81]
Brazil rK39 ICT (6 formats) Clinical + IFAT 50 84–96% 50 HEC 100% [82]
14 OD 100%
Brazil rK39 ICT Parasitology 76 83% 33 NEC 100% [78]
25 OD 84%
DAT : variable cut-offs were used, and different antigens, see original papers.
cELISA: ELISA based on crude soluble antigen; rELISA: ELISA based on recombinant antigens; FD-DAT: Freeze-dried DAT.
*CRS: Composite Reference Standard: positive if direct microscopy or culture or PCR positive.
**CRS: Composite Reference Standard:Positive if ELISA or PCR positive.
NEC: healthy dogs from non-endemic areas.
OD: dogs with other, potentially cross-reacting infectious diseases.
HEC: healthy dogs from endemic areas.
doi:10.1371/journal.pntd.0000584.t002
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test in asymptomatic dogs is crucial for a control strategy, as those
dogs are infectious, and should be targeted by the campaign.
Sensitive antigen detection tests as PCR might become a
relevant marker of infection in the future with the advantage that
they can still be used in vaccinated dogs that will be serologically
positive because of the vaccine. However, Quinnell et al (2001)
showed in a longitudinal study of naturally infected dogs how the
sensitivity of PCR was high early after infection but declined to
50% thereafter. The sensitivity of serology also varied with time,
being lowest at the time of infection but clearly superior thereafter
(93–100%). They concluded that PCR was most useful for
detection of active disease, and considered serology as more
adequate for the detection of infection [84].
I: Key questions for control.
1. What is the most cost-effective diagnostic strategy for a screen-
and-treat or screen-and-cull campaign? Novel screening
strategies based on combined, parallel or sequential use of
current available tests need to be validated.
II: Questions for research.
1. How to distinguish an antibody response due to natural
infection from that produced after vaccination in dogs?
2. What can be the contribution of novel, molecular, parasite
detection tests to clinical diagnosis in dogs?
3. What is the value of the current diagnostic tests in terms of dog
infectivity for sandflies?
Human treatment
Thirty-nine papers were retrieved from Medline/PubMed
search and four of them were considered relevant. The LILACS
database search retrieved 42 papers of which 24 were not available
from the PubMed database. Three of those 24 studies were
considered relevant, one of them, was previously identified
through the PubMed search. One paper was identified through
specific author’s name searching in PubMed. The Cochrane
Central Register of Controlled Trials search retrieved 103 trials,
three of them were conducted in the Americas but all were also
identified through the PubMed and LILACS searches. Finally,
seven papers were included for review [85–91].
Three papers were excluded from further analysis, one because
it was a second publication on the same trial [88], one for being a
retrospective study with heterogeneous therapeutic interventions
with meglumine antimoniate and case definition based on clinical
findings plus positive serology without description of the methods
and test cut-off. A minority of cases was diagnosed through
parasite identification [85], and one paper because it was a case-
control study focusing on prognostic factors [87]. The flow for the
selection and a summary of the reviewed studies appears in
Figure 3 and Table 3.
Dietze et al (1993) reported an open-label dose-escalating trial
with amphotericin B colloidal dispersion (Amphocil) in two small
groups of patients who showed similar cure rate suggesting that the
7 days was as effective as the 10 days regimen [90]. In 1995 the
same authors reported another open-label trial with Amphocil
with a shorter regime of 5 days, observing an episode of relapse
[91]. Berman et al (1998) reported the results of an open-label
phase II trial with three therapeutic regimens consisting of
liposomal amphotericin B 10, 14 or 20 mg/kg total dose; the
reported outcomes were cure, failure and relapse and the follow-
up period was of six months. This paper suggested that the lower
10mg/kg total dose was less efficacious than the higher 20mg/kg
total dose [86]. Dietze et al (2001) concluded from an open-label
dose-escalating safety and efficacy trial that sitamaquine was not
efficacious for the treatment of VL in young adults. Severe adverse
events described as renal toxicity lead to trial interruption when
using the higher dose of 3.25mg/kg/d [89].
I: Key questions for control.
1. What is the current standard of care for VL treatment in the
Americas?
2. What is the case for combination therapy for VL in the
Americas?
3. What is the standard of care in VL/HIV co-infection?
II: Questions for research.
1. What is the current efficacy of pentavalent antimonials,
amphotericin B deoxycholate and the liposomal formulations,
miltefosine and drug combinations for VL treatment in the
Americas?
2. Are there more efficacious, safer, and simpler therapeutic
schemes for VL than the current ones?
3. Can a clinical prognostic score for treatment failure be
developed to identify those cases most in need for intensive
care?
4. What is the role of non-parasite targeted drugs such as
immunomodulators, antibiotics and others in VL treatment?
Vector and animal reservoir control
Incidence and prevalence estimates of canine VL in the Americas
have been reported from several foci [2,40,92–95], but the specific
relationship between canine and human VL cases is not well
understood. Transmission in the dog population is mainly due to
infected sandfly bites but alternative routes have been proposed
such as sexual transmission and other potential insect vectors
[96–98]. The control of the animal reservoir is complex and
frequently involves combined interventions. The Brazilian Control
Program recommends a strategy based on canine culling and vector
control with insecticide spraying. Insecticide-impregnated collars
Figure 3. Flow of inclusion of studies on VL treatment.
doi:10.1371/journal.pntd.0000584.g003
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public health control measures [99].
One-hundred seventy-two papers were retrieved from Medline/
PubMed using the search strategy cited above. The LILACS
search was performed using the term visceral leishmaniasis
because no document was retrieved when using the PubMed
approach. The LILACS search was less specific and 519
documents were retrieved; 514 documents comprised an extensive
spectrum of research irrelevant for the purpose of this paper
and four of the five relevant papers were already identified
through the PubMed search. After reading the titles and the
abstracts and hand searching reference lists for related papers,
fourteen were selected for full text reading because the main
subject was at least one intervention for control VL (Figure 4)
[50,55,100–111].
Magalha ˜es et al (1980) published a retrospective –non
controlled- study on the impact of a combined intervention
consisting of human VL case treatment, culling of seropositive
dogs and insecticide spraying with DDT in 19 municipalities of the
Rio Doce Valley, State of Minas Gerais, Brazil reporting the
disappearance of human symptomatic cases after 15 years of
application of this strategy [100].
Dietze et al (1997) reported a field trial of dog screening and
culling, based on twice-yearly screening with DOT-ELISA. This
trial was conducted in three rural valleys, State of Espirito Santo,
Brazil, two benefiting from the intervention and one used as
control. At 6-months there was a 16% reduction of seroconversion
rate in dogs (36% in the intervention vs. 52% in the control
group), but this difference was not significant [101].
Braga et al (1998) reported the comparison of two strategies of
dog screening-and-culling: screening by ELISA was compared
to IFAT as routinely recommended by the National Control
Figure 4. Flow of inclusion of studies on VL control.
doi:10.1371/journal.pntd.0000584.g004
Table 3. Main characteristics of selected studies reporting treatment of human visceral leishmaniasis in Latin America.
Country Type of study
Number of
subjects
Mean patient
age (years)
Treatment
interventions Dose and route
Follow-up
period Outcomes (%) Ref.
Brazil Open-label 10 20.0 Amphotericin B
cholesterol dispersion
2.0mg/kg/d
for 10 d. I.V.
6–12 months Cure 10/10 (100) [90]
Brazil Open-label 10 19.0 Amphotericin B
cholesterol dispersion
2.0mg/kg/d
for 7 d. I.V.
6–12 months Cure 10/10 (100) [90]
Brazil Open-label 10 16.5 Amphotericin B
cholesterol dispersion
2.0mg/kg/d
for 5 d. I.V.
12 months Cure 9/10 (90) [91]
Relapse 1/10 (10)
Brazil Open-label
Phase II
13 7.6 Liposomal
amphotericin B
14mg/kg
(total) . I.V.
6 months Cure 8/13 (61) [86]
Failure 1/13 (8)
Relapse 4/13 (31)
Brazil Open-label
Phase II
4 7.5 Liposomal
amphotericin B
10mg/kg
(total) I.V.
6 months Cure 4/4 (100) [86]
Brazil Open-label
Phase II
15 10.1 Liposomal
amphotericin B
20mg/kg
(total) I.V.
6 months Cure 13/15 (87) [86]
Relapse 2/15 (13)
Brazil Open-label,
dose-escalating trial
4 19.0 WR6026 (sitamaquine) 1.0mg/kg/d
for 28 d. Oral.
12 months Cure 0/4 (0) [89]
Brazil Open-label,
dose-escalating trial
6 32.8 WR6026 (sitamaquine) 1.5mg/kg/d
for 28 d. Oral
12 months Cure 1/6 (17) [89]
Brazil Open-label,
dose-escalating trial
6 23.8 WR6026 (sitamaquine) 2.0mg/kg/d
for 28 d. Oral.
12 months Cure 4/6 (67) [89]
Brazil Open-label,
dose-escalating trial
5 23.8 WR6026 (sitamaquine) 2.5mg/kg/d
for 28 d. Oral
12 months Cure 1/5 (20) [89]
Brazil Open-label,
dose-escalating trial
1 22.0 WR6026 (sitamaquine) 3.25mg/kg/d
for 28 d. Oral
12 months Cure 0/1 (0) [89]
doi:10.1371/journal.pntd.0000584.t003
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blood sampling (7 days for ELISA vs. 80 days for IFAT). The trial
was conducted in a rural area of Northeastern Brazil where 28
communities were systematically allocated to one of the two
groups. In the ELISA arm, reduction of canine seroprevalence was
higher, probably due faster dog removal plus higher sensitivity of
the ELISA test [102].
Ashford et al (1998) reported a controlled intervention trial of
seropositive dog removal in an endemic area of the State of Bahia,
Brazil. The intervention area was subjected to screening with
FAST-ELISA and removal of seropositive dogs, in the control area
no intervention was carried out. A significant reduction of dog
seroconversion rate in the intervention area as compared to
control was observed, and a significantly lower number of VL
cases reported to health facilities in the intervention area [50].
Paranhos-Silva et al (1998) report a follow- up study of several
clusters of seronegative dogs in Jequie ´, State of Bahia, Brazil. The
initial prevalence of infection among 1681 dogs was 23.5%. After
serological screening every six months for 18 months and removal
of the seroconverters, the annual incidence rate of infection was
6.55 cases/100dog-years. The migration of dogs between clusters
was 2.3 cases/100 dog-years. This study is relevant because as
highlights the challenges posed by dog migration for any control
program dealing with the canine reservoir [103].
Da Silva et al (2000) reported a phase III vaccine field trial in
seronegative dogs screened with IFAT and FML-ELISA and
exposed to fucose-mannose-ligand vaccine in three subcutaneous
doses at 21 day intervals. Control arm was treated with saline
placebo. Endpoints were symptomatic VL or death, seroconver-
sion rates in FML-ELISA and conversion of leishmanin skin test
composed of crude L. donovani antigen. Follow-up evaluations were
performed at 2, 7, 13 and 24 months. A significant difference in
the three endpoints was observed during the trial. The overall
efficacy to prevent symptomatic VL disease was 75% [104].
Giffoni et al (2002) reported the effect of application of a
65% permethrin spot-on formulation on canine VL infection and
sandfly abundance. A decrease of canine VL prevalence was
observed in the intervention area compared with increased
prevalence in the control area. No effect was observed on sandfly
population [105].
Feliciangeli et al (2003) described a controlled trial of pyrethroid
(l-cyhalothrin) indoor spraying every 5 month and organophos-
phate (fenitrothion) ultra-low volume spatial fogging around the
houses twice a month for ten months in one intervention
compared to one control area. The main vector captured was
Lu. longipalpis. A significant decrease of sandfly abundance was
observed, with a residual effect of indoor spraying of 3 months.
Main limitation of this study was the specific construction style of
the houses: completely cemented, plastered and oil-painted walls
and zinc roofs, which lowers its external validity [106].
De Oliveira et al (2003) reported the evaluation of routine
combined control measures of seropositive dog-culling and
insecticide spraying during six years. The intensity of the
application of control measures correlated with human VL
incidence, the coverage of canine surveys, the number of canine
surveyed and the number of buildings submitted to insecticide
spraying [107].
Reithinger et al (2004) reported a controlled field trial to
evaluate the effectiveness of insecticide impregnated collars to
prevent infection detected through serological tests or DNA
detection by PCR assay in one intervention compared to one
control area. The authors failed to detect a significant difference
between groups in the incidence of new infections but they
demonstrated a significant reduction of antibody titers in the collar
protected dogs. Mathematical modeling using the results obtained
in this study suggests that dog collars would be a better alternative
than dog culling [55].
Moreira et al (2004) reported the incidence rates of canine
Leishmania infection in a cohort of dogs submitted to an optimized
culling strategy consisting of: (i) ELISA screening of serum samples;
(ii) shortening of the time interval from serodiagnosis to removal of
dogs; (iii) screening a high proportion of the dog population. They
demonstrated that the incidence of canine infection remained stable
through 2.5 years of observation under this strategy but the study
had no control arm for comparison. A high replacement rate by
susceptible puppies and already infected dogs was observed [108].
Courtenay et al (2007) reported the barrier effect, the 24-h
mortality rate and the human landing rates of Lu. longipalpis in
households using deltamethrin-impregnated bednets compared
others using untreated bed nets. The study described a 39%
increase in barrier capacity of the impregnated bednets, 80%
reduction in sandfly landing rates on humans and 98% increase in
the 24-h sandfly mortality rates. The study was done under field
conditions with a small number of observations during a very short
period of exposure to the treated bednets (three days) and the
residual effect was not measured. However this intervention
should be explored further because it could bring an additional
benefit in areas where malaria is also endemic [109].
Costa et al (2007) reported a randomized community interven-
tion trial to compare the effect of four strategies on human VL, as
follows: (i) spraying houses and animal pens with pyrethroid
insecticide; (ii) spraying houses and eliminating seropositive dogs;
(iii) combination of spraying houses and animal pens plus
eliminating seropositive dogs; and (iv) spraying houses only as the
reference comparator. The outcome was evaluated by measuring
incidence of seroconversion in humans six months after the
application of interventions. The results indicated a positive effect
of canine removal on incidence of leishmanial infection in men but
surprisingly, the combination of dog culling plus outdoor spraying
of peridomestic animal shelters failed to demonstrate any effect.
The relevance of this study is that it constitutes the first attempt
to measure the effect of combined interventions on human VL
incidence [110].
De Souza et al (2008) reported a randomized community
intervention trial to compare the effect of (i) pyrethroid insecticide
spraying; (ii) pyrethroid insecticide spraying plus culling of sero-
positive dogs with (iii) no intervention. The interventions were
maintained for two years and outcomes were registered every year,
insecticide spraying was performed every 6 months. Although a
lower incidence was observed in the groups submitted to
interventions and that reduction was more intense after two years,
the study failed to detect statistically significant differences [111].
The summarized characteristics and main limitations of these
studies are shown in Table 4.
Key questions for control.
1. What is the most cost-effective control strategy for VL?
2. How to conduct a valid impact evaluation?
3. Can general support measures (nutritional rehabilitation and
housing improvement) be targeted to VL endemic areas?
4. What is the potential impact of current dog vaccines on
transmission?
Questions for research.
1. What are the determinants of dog infectiousness for the sandfly
vector?
2. What are the determinants of dog susceptibility to infection?
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in dogs and to reduce infectiousness for the sandfly vectors?
4. What is the effectiveness of insecticide- impregnated dog collars
to prevent human and canine infection?
5. What is the efficacy/effectiveness of alternative vector control
devices (insecticide treated nets, curtains, etc) in the prevention
of VL?
Discussion
Research gaps
This review of evidence related to VL control in Latin America
revealed that a lot of work remains to be done in order to clarify the
dynamics of Leishmania transmission in human, canine and vector
populations. The exact burden of disease remains largely unknown.
The increasing trend of VL cases observed in Brazil and the spread
oftransmissiontopreviouslynotaffectedareasraisedoubtsaboutthe
impact of ongoing control measures. The determinants of human
infection and of symptomatic disease are also poorly understood
with the exception of the nutritional status in young children.
To diagnose VL in humans the rK39-ICT has clear advantages
over the IFAT or ELISA based tests that are widely used in Latin
America. The DAT assay has shown similar diagnostic performance
but is not as user-friendly as the rK39. The research priorities in this
field should be geared towards diagnostic accuracy studies in large
prospective trials (phase-3) and to study diagnostic performance in
specific groups such as HIV co-infected patients. Current treatment
practice in VL in Latin-America is based on rather weak scientific
evidence. It is worrisome that case fatality rates remain high and are
even increasing, at least in Brazil. The lack of clinical evidence from
the region is very worrying. We retrieved not a single phase-3
randomized controlled trial on VL conducted in the Americas.
Nowadays, one phase-2 trial with miltefosine is ongoing and two
Brazilian large randomized controlled trials with liposomal ampho-
tericin B, amphotericin B deoxycholate and meglumine antimoniate
are expected to initiate recruitment in 2009. The research priorities
include well-designed clinical trials with pentavalent antimonials,
amphotericin B deoxycholate and the liposomal formulations,
miltefosine and drug combinations. Although the resistance to
antimonials observed in India is less relevant in Latin America, drug
combinations are attractive because their potential for shortening
treatment schemes and reduction of toxicity. Clinical factors
associated with treatment failure should be studied to contribute to
the development of a prognostic score that allows early interventions
to reduce case fatality rates [14,87].
Control interventions targeting the dog reservoir for culling/
treatment require accurate assays able to detect the asymptomatic
infections as well as the symptomatic dogs. Validating such tests is
no easy task, as there is no adequate gold-standard for the diagnosis
of asymptomatic infection. PCR-assays seem to be very attractive
but estimating their accuracy and reproducibility still constitutes a
research priority. Moreover, novel screening strategies based on
combined, parallel or sequential use of current available tests needs
to be validated. Another challenge faced in canine diagnosis is the
distinction of positive serology results produced by natural infection
from those induced by vaccines. The development and proper
validation of testswithcapacitytodiscriminate both phenomenaare
crucial to avoid interference with concomitant interventions
including dog culling and vaccination in the same area. Further-
more, the study of the determinants of dog infectiousness for the
sandfly vector is essential to define the best culling strategy
[112,113] and the determinants of dog susceptibility to infection
[114] is crucial for the design of canine vaccine trials.
Some of the problems with the design of the community
intervention trials we reviewed are related to the lack of accurate
diagnostic methods to define the relevant outcomes in the human
and canine population. Furthermore, the definition of a control
group is challenging because of an obvious ethical dilemma. The
heterogeneity of disease transmission within the study area often
generated imbalances in the baseline comparisons among groups
and the random allocation process is also complex because of the
mobility of the human, canine and vector population. Most of the
reported community trials used a too limited number of clusters for
comparison (usually a one to one comparison). In spite of all those
limitations a relevant number of reports could be reviewed in detail,
showing no strong evidence for a significant impact on VL
transmission for any of the interventions reviewed. Canine culling
seems to be the least acceptable intervention at community level for
obvious reasons and has low efficiency due to high replacement rate
of eliminated dogs with susceptible puppies [103,115,116]. Vector
control interventions are better accepted by the affected populations
and mathematical models suggested encouraging efficacy, but they
need further study. Better knowledge of vector seasonality and
behavior is required for proper timing of these interventions. The
current evidence indicates that spatial fogging is useless and that the
residual effect of house wall spraying is very short [106,117].
Insecticide impregnated collars seem to have a longer residual effect
[56] and theoretical advantages over the other methods and should
be studied in larger and well-designed controlled trials. The potential
emergence of resistance to insecticides should also be considered for
the long-term planning of any vector control intervention [118].
Canine and human vaccine development needs to be priori-
tized. The dog vaccines already registered in Brazil have some
protective effect against canine VL but none of them were
properly evaluated as control measures against human VL
[119,120]. Such evaluation is challenging as field trials should
include relevant canine endpoints, related to dog infectiousness for
the sandfly vector, as well as relevant human endpoints, that
include symptomatic and asymptomatic infections in order to
obtain precise estimates of the vaccine effect on transmission rates.
Human vaccine development is expected to take at least several
years to obtain efficacious and safe candidates for clinical trials.
Furthermore, the surrogate markers of the desired protective effect
are not well understood and the definition of target population for
such products will be a matter of intense debate.
The role of sylvatic and peridomestic animals such as foxes,
marsupials and rodents in some relevant VL transmission
scenarios deserves more specific research [6].
Last but not least, in countries such as Brazil, where the
government has put the elimination of hunger as a political
priority, targeted nutritional support in VL risk areas would be an
interesting and probably cost-effective intervention from a societal
perspective. Similarly, schemes for the improving of housing and
waste management as well as other general measures involving
active community participation should be encouraged [121,122].
Finally, the strengthening of the surveillance system capacity is
essential to avoid the underreporting of human cases [123] and to
follow-up the infection behavior in canine population. Strong
surveillance will certainly contribute to improve data quality for
decision-makers in this complex scenario.
Concluding remarks
The elimination of zoonotic VL in Latin America is not (yet) a
realistic goal taking into consideration the complexity and diversity
of its transmission scenarios, the scientific knowledge gaps and the
lack of adequate and properly validated interventions. Many
countries perceive the burden of leishmaniasis as negligible; there
Visceral Leishmaniasis in Latin America
www.plosntds.org 14 January 2010 | Volume 4 | Issue 1 | e584is not much political support nor funding for VL control. The
zoonotic nature of transmission is an additional constraint that
limits the impact of the few known effective prevention and control
interventions. Nonetheless we believe the improved control of VL
is possible if the region builds the political will, develops a more
coherent regional control policy, and invests in better case
management and epidemiological surveillance systems. The
implementation of a focused research agenda to support such
control initiative is essential.
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